Navigation Links
Personlized dendritic cell vaccine increases survival in patients with deadly brain cancer
Date:3/17/2011

a multi-center trial, and UCLA is the only site offering it in California.

It has recently been discovered that there are at least three subtypes of glioblastoma: proneural, proliferative and mesenchymal. During the course of her study, Liau and her colleagues saw that one group of patients seemed to be responding very well to the vaccine and examined their tumors using a microarray analysis of their DNA. They found that those with a gene expression profile identifying their cancers as mesenchymal responded better to the vaccine.

The finding was surprising, Liau said, because patients with the mesenchymal subtype generally have more aggressive disease and shorter survival than those with the other subtypes. In patients with this type of glioblastoma, several genes that modulate the immune system are dysregulated, meaning they don't work properly. Liau speculates that the vaccine helped replenish the immune system, allowing that subset of patients to more easily fight the brain cancer.

"Glioblastoma remains one of the diseases for which there is no curative therapy and the prognosis for patients with primary malignant brain tumors remains dismal," the study states. "Our results suggest that the mesenchymal gene expression profile may identify an immunogenic sub-group of glioblastoma that may be more responsive to immune-based therapies."

Brad Silver, 41, who grew up in Southern California and now lives in a Cleveland suburb, was diagnosed with glioblastoma in 2003 and was told that he had, at best, two months to live. He was stunned.

"I was 33 years and my wife was seven months pregnant with my son," said Silver, a college water polo instructor. 'I didn't think I was going to live to see my son born, let alone grow up."

Silver sought a second opinion at UCLA and the golf-ball sized tumor in his left lateral lobe was removed. He underwent radiation and chemotherapy and enrolled in the vaccine clinical trial.
'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. For first time, scientists show an HIV vaccine impacts the genetic makeup of the virus
2. Vaccine made with synthetic gene protects against deadly pneumonia
3. Media advisory -- Partnering to Fight TB: The Role of a TB Vaccine PDP
4. Saint Louis University findings: Dont pitch stockpiled avian flu vaccine
5. Researchers test inhalable measles vaccine
6. Therapeutic AIDS vaccine designed by HIVACAT reduces the viral load in the majority of AIDS patients
7. H1N1 pandemic points to vaccine strategy for multiple flu strains
8. Team creates novel vaccine that produces strong immunity against cocaine high
9. New vaccine to assist worldwide eradication of polio
10. Experts converge at Arizona State University for first preventive cancer vaccine conference
11. Blame the environment: Why vaccines may be ineffective for some people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... 2009 / b3c newswire / - DuoCort ... rare and life threatening disease adrenal insufficiency. The release ... hydrocortisone dosing closely resembles the physiological secretion pattern. The ... Endocrinology, a leading scientific journal for endocrinology. ...
... for the organism, and this is true even for the ... of present marine mammals initiated their return to the oceans, ... Dr. Michael Berenbrink and his colleagues at Liverpool University have ... to the muscles during locomotion, has been modified in seals ...
... pregnancy or in previous pregnancies can predict the,likelihood ... according to research carried out by an,international group ... to predict more easily which women might need ... enabling new research to improve clinical management of ...
Cached Biology News:DuoCort: New chronotherapy for adrenal insufficiency 2DuoCort: New chronotherapy for adrenal insufficiency 3Natural-born divers and the molecular traces of evolution 2Complications early in pregnancy or in previous pregnancies adversely affect existing or subsequent pregnancies 2Complications early in pregnancy or in previous pregnancies adversely affect existing or subsequent pregnancies 3
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... , , FRAMINGHAM, ... HTWR ) (ASX: HIN) today confirmed that trading ... Exchange ("ASX") was temporarily suspended for the reasons stated below. ... NASDAQ is also temporarily suspended. Based on discussions with ...
... , ANNAPOLIS, Md., Sept. 1 PharmAthene, Inc. ... medical countermeasures against biological and chemical threats, announced today that ... Investment Conference 2009. The Company is scheduled to present ... the Hubbard Salon (5th Floor) at the New York Palace ...
... , , DALLAS, Sept. 1 ... (OTC Bulletin Board : ACCP) announced today that ... be held September 9-11, 2009 at the New York Palace Hotel in New ... to speak on Friday, September 11, 2009 at 10:50 am EDT in the ...
Cached Biology Technology:HeartWare International, Inc. Temporary Suspension of Trading 2HeartWare International, Inc. Temporary Suspension of Trading 3Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference 2Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference 3
Mouse monoclonal antibody to FMN2 - formin 2...
...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... (KLF15) KLF15 is a Cys2-His2 zinc ... in the liver, kidneys, heart, and skeletal ... Polyclonal antibody produced in rabbits immunized with ... of human KLF15 with an internal ID ...
Biology Products: